tuberculosis is a highly infectious and potentially fatal disease accompanied by wasting symptoms, which cause severe metabolic changes in infected people. in this study we have compared the effect of mycobacteria infection on the level of metabolites in blood of humans and mice and whole zebrafish larvae using one highly standardized mass spectrometry pipeline, ensuring technical comparability of the results. Quantification of a range of circulating small amines showed that the levels of the majority of these compounds were significantly decreased in all three groups of infected organisms. Ten of these metabolites were common between the three different organisms comprising: methionine, asparagine, cysteine, threonine, serine, tryptophan, leucine, citrulline, ethanolamine and phenylalanine. The metabolomic changes of zebrafish larvae after infection were confirmed by nuclear magnetic resonance spectroscopy. Our study identified common biomarkers for tuberculosis disease in humans, mice and zebrafish, showing across species conservation of metabolic reprogramming processes as a result of disease. Apparently, the mechanisms underlying these processes are independent of environmental, developmental and vertebrate evolutionary factors. The zebrafish larval model is highly suited to further investigate the mechanism of metabolic reprogramming and the connection with wasting syndrome due to infection by mycobacteria. Infection with Mycobacterium tuberculosis (Mtb) can result in tuberculosis (TB) that currently is newly affecting over 10 million people per year and leading to 1.6 million deaths annually 1. However, the majority of people that have been infected with Mtb, estimated to be in the order of 2 billion, do not experience any symptoms in the presence of positive immunological (blood or skin) test results. In patients diagnosed with TB, the disease is uniformly characterized by a metabolic wasting syndrome that leads to heavy weight loss that concurs with a strong reduction of muscle mass. TB has therefore historically earned the name of "consumption". Novel tools for control of TB should include not only better treatments, including attention to the deleterious effects of wasting syndrome, but also needs to include cost-effective assays for robust and sensitive diagnosis of TB 2. Recent metabolomics studies have identified valuable diagnostic metabolic blood markers that can discriminate TB patients from healthy individuals 3-13. This appeared to be applicable to very different population groups, ranging from trans-Africa, China, Georgia, and Indonesia, and therefore highlighting that blood metabolites are robust and validating biomarkers for TB progression. These studies used mostly mass spectrometry (MS) and